References
- Cohen SM, Petryk M, Varma M, et al. Non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue. Oncologist 2006;11:1100–1117.
- Wotherspoon A, Doglioni C, Diss T, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-ass0ciated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993;342: 575–577.
- Bayerdörffer E, Neubarer A, Rudolph B, et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. Lancet 1995;345:1519.
- Roggero E, Zucca E, Pinotti G, et al. Eradcation of Helicobacter pylori infection in primary low-grade gastric lymphoma of mucosa-associated lymphoid tissue. Ann Intern Med 1995;122:767–769.
- Nakamura S, Matsumoto T, Suekane H, et al. Long-term clinical outcome of Helicobacter pylori eradication for gastric mucosa-associated lymphoid tissue lymphoma with a reference to second-line treatment. Cancer 2005;104:532–540.
- Tsang RW, Gospodarowicz MK, Pintilie M, et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol 2003;21:4157–4164.
- McLaughlin P, Grillo-Loper AJ, Levy R, et al. Rituximab chimeric-CD20 monoclonal antibody therapy: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825–2833.
- Martinelli G, Laszlo D, Ferreri Andrés JM, et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol 2005;23:1979–1983.
- Conconi A, Martinelli G, Thiéblemont C, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 2003;102:2741–2745.
- Cheson BD, Horning SJ, Coiffer B, et al. Report of an international workshop to standardized response criteria for non-Hodgkin's lymphoma. J Clin Oncol 1999;17:1244–1253.
- Musshoff K. Clinical staging classification of non-Hodgkin's lymphomas. Strahlentherapy 1977;153:218–221.
- Thiéblemont C, Bastion Y, Berger F, et al. Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: analysis of 108 patients. J Clin Oncol 1997;15:1624–1630.
- Papaxoinis G, Fountzilas G, Rontogianni D, et al. Low-grade mucosa-associated lymphoid tissue lymphoma: a retrospective analysis of 97 patients by the Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol 2008;19:780–786.
- Raderer M, Wöhrer S, Streubel B, et al. Assessment of disease dissemination in gastric compared with extragastric mucosa-associated lymphoid tissue lymphoma using extensive staging: a single-center experience. J Clin Oncol 2006;24:3136–3141.
- Thiéblemont C, Berger F, Dumontet C, et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood 2000;95:802–806.
- Zinzani PL, Magagnoli M, Galieni P, et al. Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma:analysis of 75 patients. J Clin Oncol 1999;17:1254–1258.
- Arcaini L, Burcheri S, Rossi A, et al. Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination. Oncologist 2006;11:285–291.
- Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin's lymphoma. Cancer 2010;116:106–114.
- Ohmachi K, Ando K, Ogura M, et al. Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci 2010;101:2059–2064.
- Witzig TE, White CA, Wiseman GA, et al. Phase 1/2 trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20 + B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999;17:3793–3803.